Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors-Reference-Cited by-同舟云学术

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors

Published:2003-06 Issue:6 Volume:14 Page:922-930
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Nakagawa K.,Tamura T.,Negoro S.,Kudoh S.,Yamamoto N.,Yamamoto N.,Takeda K.,Swaisland H.,Nakatani I.,Hirose M.,Dong R.-P.,Fukuoka M.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/14/6/922/365222/mdg250.pdf

Reference24 articles.

1. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy;Raymond;Drugs,2001

2. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin;Baselga;J Clin Oncol,2000

3. ZD1839 (‘Iressa’) as an anticancer agent;Baselga;Drugs,2000

4. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies;Hidalgo;J Clin Oncol,2001

5. The epidermal growth factor receptor and its inhibition in cancer therapy;Woodburn;Pharmacol Ther,1999

Cited by 248 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Busting the Breast Cancer with AstraZeneca’s Gefitinib;Advances in Pharmacological and Pharmaceutical Sciences;2023-12-04

2. Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study;Cancer Chemotherapy and Pharmacology;2023-07-31

3. Pharmacokinetics, bioequivalence, and safety studies of gefitinib tablet formulations: A randomized, open-label, two-period, two-sequence crossover study in Chinese healthy volunteers;Journal of Drug Delivery Science and Technology;2023-06

4. Phase 1 study of DS‐1205c combined with gefitinib for EGFR mutation‐positive non‐small cell lung cancer;Cancer Medicine;2023-01-09

5. Historical development of EGFR-targeted therapy;Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC;2023